[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Streptozocin.]
[L04AA27, fingolimod, Daclizumab may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daclizumab.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mercaptopurine.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Teniposide.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Thalidomide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Daclizumab is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tioguanine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Triamcinolone.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Trifluridine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Daclizumab.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Belimumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipilimumab.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Daclizumab is combined with Belatacept.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Vindesine.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Zidovudine.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Brentuximab vedotin.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daclizumab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Gemcitabine.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Daclizumab.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pertuzumab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Carfilzomib.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Teriflunomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Daclizumab is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Aldosterone.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bendamustine.]
[L04AA29, tofacitinib, Daclizumab may increase the immunosuppressive activities of Tofacitinib.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponatinib.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Raxibacumab.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dimethyl fumarate.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Daclizumab is combined with Everolimus.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibrutinib.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Daclizumab is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Betamethasone.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Siltuximab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ramucirumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Vedolizumab.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Daclizumab is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Daclizumab is combined with Peginterferon beta-1a.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pembrolizumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaparib.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Nivolumab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Daclizumab is combined with Panobinostat.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleomycin.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Alirocumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Evolocumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarucizumab.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Trabectedin.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Daclizumab is combined with Asfotase alfa.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mepolizumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Daratumumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Elotuzumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tetanus immune globulin, human.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixekizumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Reslizumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Obiltoxaximab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Atezolizumab.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Daclizumab is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Arsenic trioxide.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaratumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Brodalumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Avelumab.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Daclizumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dupilumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Antilymphocyte immunoglobulin (horse).]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Daclizumab is combined with Linezolid.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Durvalumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Capecitabine.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Inotuzumab ozogamicin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Daclizumab is combined with Vorinostat.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Daclizumab is combined with Raltitrexed.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Budesonide.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Emicizumab.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Carbamazepine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daclizumab.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Erenumab.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Baricitinib.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mogamulizumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Galcanezumab.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Carmustine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Caplacizumab.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Daclizumab is combined with Siponimod.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Romosozumab.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Daclizumab.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Risankizumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Polatuzumab vedotin.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Upadacitinib.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Brolucizumab.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Daclizumab is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Daclizumab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab deruxtecan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Daclizumab is combined with Diroximel fumarate.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Teprotumumab.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Eptinezumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanimod.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bexarotene.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Daclizumab is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Daclizumab is combined with Chloramphenicol.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sacituzumab govitecan.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednidene.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Daclizumab is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Stepronin.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Satralizumab.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Daclizumab.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludarabine.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Margetuximab.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Voclosporin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinolone acetonide.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daclizumab.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Amivantamab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sotrovimab.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cisplatin.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Aducanumab.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Daclizumab is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Anifrolumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tisotumab vedotin.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ropeginterferon alfa-2b.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sutimlimab.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Deucravacitinib.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tremelimumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ublituximab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Panitumumab.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Hepatitis B immune globulin.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Nelarabine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ciclesonide.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Imatinib.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cyclophosphamide.]
[S01XA18, cyclosporine, Daclizumab may increase the immunosuppressive activities of Cyclosporine.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Daclizumab.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Daclizumab.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Desoximetasone.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Oxaliplatin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Daclizumab.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Daclizumab.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixabepilone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Daclizumab.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Difluocortolone.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Daclizumab.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Lenalidomide.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Daclizumab.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirolimus.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Human Rho(D) immune globulin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bortezomib.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxorubicin.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Temozolomide.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Daclizumab.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Daclizumab is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Trofosfamide.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Human varicella-zoster immune globulin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinorelbine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Epirubicin.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Carboplatin.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Daclizumab.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Estramustine.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Daclizumab.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Daclizumab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Daclizumab.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Daclizumab.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Etoposide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Daclizumab.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexrazoxane.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cladribine.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludrocortisone.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorometholone.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorouracil.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dasatinib.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sorafenib.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Daclizumab is combined with Irinotecan.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Altretamine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxyurea.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ifosfamide.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Daclizumab is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Daclizumab is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Indomethacin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daclizumab.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Eculizumab.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ranibizumab.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Tocilizumab.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Daclizumab is combined with Abatacept.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitomycin.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Lomustine.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Daclizumab is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mechlorethamine.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Daclizumab is combined with Melphalan.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Daclizumab is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pemetrexed.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Daclizumab is combined with Methotrexate.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Methylprednisolone.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Daclizumab is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolic acid.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Daclizumab.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Daclizumab is combined with Docetaxel.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Amsacrine.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilonacept.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pentostatin.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Edrecolomab.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daclizumab.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Golimumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Daclizumab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ustekinumab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Canakinumab.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisone.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Procarbazine.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Daclizumab is combined with Propylthiouracil.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Daclizumab.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulfasalazine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab emtansine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone butyrate.]
